G J Kelloff

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA
    Urology 57:46-51. 2001
  2. ncbi request reprint Progress in cancer chemoprevention
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 889:1-13. 1999
  3. ncbi request reprint Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
    R Lieberman
    Chemoprevention Branch, National Cancer Institute, Rockville, MD 20852, USA
    Clin Chem 44:420-7. 1998
  4. ncbi request reprint Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model
    R A Lubet
    National Cancer Institute, Division of Cancer Prevention and Control, Bethesda, MD, USA
    Int J Cancer 72:95-101. 1997
  5. ncbi request reprint Potential use of lipoxygenase inhibitors for cancer chemoprevention
    V E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Expert Opin Investig Drugs 9:2121-38. 2000
  6. ncbi request reprint Cancer chemoprevention: progress and promise
    G J Kelloff
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Eur J Cancer 35:2031-8. 1999
  7. ncbi request reprint Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays
    V E Steele
    Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Carcinogenesis 21:63-7. 2000
  8. ncbi request reprint Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model
    R A Lubet
    NCI DCP, Bethesda, MD 20892, USA
    Carcinogenesis 19:1345-51. 1998
  9. ncbi request reprint Surrogate end-point biomarkers in chemopreventive drug development
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7322, USA
    IARC Sci Publ 154:13-26. 2001
  10. doi request reprint I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
    A D Barker
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Pharmacol Ther 86:97-100. 2009

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA
    Urology 57:46-51. 2001
    ..Cohort selection should be based on various patient characteristics (stage of the disease, previous cancers or premalignant lesions, or high risk factors) and should be conducted within the context of standard treatment...
  2. ncbi request reprint Progress in cancer chemoprevention
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 889:1-13. 1999
    ..g., local delivery to cancer targets, agent combinations, and pharmacodynamically guided dosing)...
  3. ncbi request reprint Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
    R Lieberman
    Chemoprevention Branch, National Cancer Institute, Rockville, MD 20852, USA
    Clin Chem 44:420-7. 1998
    ..g., laser capture microdissection and cDNA chip microarrays that assess gene expression patterns of precancerous and cancerous lesions...
  4. ncbi request reprint Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model
    R A Lubet
    National Cancer Institute, Division of Cancer Prevention and Control, Bethesda, MD, USA
    Int J Cancer 72:95-101. 1997
    ..Surprisingly, treatment with DMBA plus PEITC, a potent inhibitor of cytochrome P450 2E1, actually increased the multiplicity of tumors relative to that observed with DMBA alone...
  5. ncbi request reprint Potential use of lipoxygenase inhibitors for cancer chemoprevention
    V E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Expert Opin Investig Drugs 9:2121-38. 2000
    ..Based on currently available data, it is expected that the prevention of lung and prostate cancer will be initially studied in human trials of LO inhibitors...
  6. ncbi request reprint Cancer chemoprevention: progress and promise
    G J Kelloff
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Eur J Cancer 35:2031-8. 1999
    ..The large number of chemoprevention research programmes now ongoing ensures that the promise of chemoprevention will continue to be realised in the next decade...
  7. ncbi request reprint Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays
    V E Steele
    Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Carcinogenesis 21:63-7. 2000
    ..Such anticancer mechanisms may well be responsible for the cancer preventive efficacies seen in both experimental and human studies...
  8. ncbi request reprint Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model
    R A Lubet
    NCI DCP, Bethesda, MD 20892, USA
    Carcinogenesis 19:1345-51. 1998
    ..Although this intermittent treatment did inhibit the appearance of new tumors during each of the periods that vorozole was administered, it did not cause regression of palpable cancers...
  9. ncbi request reprint Surrogate end-point biomarkers in chemopreventive drug development
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7322, USA
    IARC Sci Publ 154:13-26. 2001
    ....
  10. doi request reprint I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
    A D Barker
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Pharmacol Ther 86:97-100. 2009
    ....